DISC1 inhibits GSK3β activity to prevent tau hyperphosphorylation under diabetic encephalopathy
- PMID: 36070513
- DOI: 10.1002/biof.1884
DISC1 inhibits GSK3β activity to prevent tau hyperphosphorylation under diabetic encephalopathy
Abstract
Diabetic encephalopathy (DE) is a common complication of type 2 diabetes (T2D), especially in those patients with long T2D history. Persistent high glucose (HG) stimulation leads to neuron damage and manifests like Alzheimer's disease's pathological features such as neurofilament tangle. However, the precise mechanism of high-glucose-induced tau hyperphosphorylation is not fully revealed. We here gave evidence that Disrupted in schizophrenia 1 protein (DISC1) could interact with glycogen synthase kinase 3β (GSK3β) and inhibit its activity to prevent tau hyperphosphorylation. By using DB/DB mice as animal model and HG-treated N2a cell as cell model, we found that DISC1 was downregulated both in vivo and in vitro, complicated with Tau hyperphosphorylation and GSK3β activation. Further, we identified DISC1 interacted with GSK3β by its 198th-237th amino acid residues. Overexpression of full length DISC1 but not mutated DISC1 lacking this domain could prevent HG induced tau hyperphosphorylation. Taken together, our work revealed DISC1 could be an important negative modulators of tau phosphorylation, and suggested that preservation of DISC1 could prevent HG induced neuron damage.
Keywords: DISC1; GSK3β; diabetic encephalopathy; tau hyperphosphorylation.
© 2022 International Union of Biochemistry and Molecular Biology.
References
REFERENCES
-
- Andreadi A, Bellia A, Di Daniele N, Meloni M, Lauro R, Della-Morte D, et al. The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: a target for new therapies against cardiovascular diseases. Curr Opin Pharmacol. 2021;62:85-96. https://doi.org/10.1016/j.coph.2021.11.010
-
- Rizzo MR, Di Meo I, Polito R, Auriemma MC, Gambardella A, di Mauro G, et al. Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment. Pharmacol Res. 2022;176:106062. https://doi.org/10.1016/j.phrs.2022.106062
-
- Barthold D, Gibbons LE, Marcum ZA, Gray SL, Dirk KC, Grabowski TJ, et al. Alzheimer's disease-related neuropathology among patients with medication treated type 2 diabetes in a community-based autopsy cohort. J Alzheimers Dis. 2021;83:1303-12. https://doi.org/10.3233/JAD-210059
-
- Rad SK, Arya A, Karimian H, Madhavan P, Rizwan F, Koshy S, et al. Mechanism involved in insulin resistance via accumulation of beta-amyloid and neurofibrillary tangles: link between type 2 diabetes and Alzheimer's disease. Drug Des Devel Ther. 2018;12:3999-4021. https://doi.org/10.2147/DDDT.S173970
-
- Khan MS, Ikram M, Park TJ, Kim MO. Pathology, risk factors, and oxidative damage related to type 2 diabetes-mediated Alzheimer's disease and the rescuing effects of the potent antioxidant anthocyanin. Oxid Med Cell Longev. 2021;2021:4051207. https://doi.org/10.1155/2021/4051207
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
